Department of Oncology, Mayo Clinic, Rochester, MN.
Division of Hematology, Mayo Clinic, Rochester, MN.
JCO Oncol Pract. 2023 Sep;19(9):750-758. doi: 10.1200/OP.23.00118. Epub 2023 Jun 19.
In response to the COVID-19 pandemic, many cancer practices rapidly adopted telehealth services. However, there is a paucity of data regarding ongoing telehealth visit utilization beyond this initial response. The purpose of this study was to assess changes in variables associated with telehealth visit utilization over time.
This is a cross-sectional, year-over-year, retrospective analysis of telehealth visits conducted across a multisite, multiregional cancer practice in the United States. Multivariable models examined the association of patient- and provider-level variables with telehealth utilization across outpatient visits conducted over three 8-week periods from July to August in 2019 (n = 32,537), 2020 (n = 33,399), and 2021 (n = 35,820).
The rate of telehealth utilization increased from <0.01% (2019) to 11% (2020) to 14% (2021). The most significant patient-level factors associated with increased telehealth utilization included nonrural residence and age ≤65 years. Among patients residing in rural settings, video visit utilization rates were significantly lower and phone visit utilization rates were significantly higher compared with patients from nonrural residences. Regarding provider-level factors, widening differences in telehealth utilization were observed at tertiary versus community-based practice settings. Increased telehealth utilization was not associated with duplicative care as per-patient and per-physician visit volumes in 2021 remained consistent with prepandemic levels.
We observed continuous expansion in telehealth visit utilization from 2020 to 2021. Our experiences suggest that telehealth can be integrated into cancer practices without evidence of duplicative care. Future work should examine sustainable reimbursement structures and policies to ensure accessibility of telehealth as a means to facilitate equitable, patient-centered cancer care.
应对 COVID-19 大流行,许多癌症治疗机构迅速采用了远程医疗服务。然而,关于这一初始反应之后远程医疗访问利用的持续情况的数据却很少。本研究的目的是评估随时间推移与远程医疗访问利用相关的变量变化。
这是一项在美国多地点、多区域癌症治疗机构中进行的跨年度、回顾性的远程医疗访问横断面研究。多变量模型检查了患者和提供者层面变量与 2019 年 7 月至 8 月的三个 8 周期间(n = 32537)、2020 年(n = 33399)和 2021 年(n = 35820)进行的门诊远程医疗利用之间的关联。
远程医疗利用率从<0.01%(2019 年)增加到 11%(2020 年),再增加到 14%(2021 年)。与增加远程医疗利用率最显著相关的患者层面因素包括非农村居住和年龄≤65 岁。在农村居住的患者中,与非农村居住的患者相比,视频访问利用率显著较低,而电话访问利用率显著较高。关于提供者层面的因素,在三级与社区实践环境中,远程医疗利用率的差距明显扩大。与大流行前水平相比,2021 年每位患者和每位医生的就诊量保持不变,因此,远程医疗的利用并未导致重复治疗。
我们观察到 2020 年至 2021 年远程医疗访问利用率的持续增长。我们的经验表明,远程医疗可以整合到癌症治疗中,而不会出现重复治疗的情况。未来的工作应研究可持续的报销结构和政策,以确保远程医疗作为促进公平、以患者为中心的癌症护理的一种手段的可及性。